Ceftriaxone-resistant<i>Neisseria gonorrhoeae</i>, Puerto Rico

Scharbaai-Vázquez, Ramón; González-Caraballo, Ana L.; Torres-Bauza, L J

doi:10.1136/sextrans-2014-051716

Cited by 3 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 13 The ceftriaxone MIC 50 for these 2010–11 N. gonorrhoeae Cuban isolates was 0.008–0.016 mg/L, 13 which is substantially higher than the ceftriaxone MIC 50 for Jamaican isolates (0.002 mg/L) in our present study. In 2014, Puerto Rico reported one ceftriaxone-resistant N. gonorrhoeae isolate, 18 but, to the best of our knowledge, no other ceftriaxone-resistant N. gonorrhoeae isolates have been reported from the Caribbean. Due to the highly limited number of N. gonorrhoeae AMR surveillance studies, it is possible that additional ceftriaxone-resistant strains are spreading in the Caribbean.…”

Section: Discussionmentioning

confidence: 89%

Antimicrobial susceptibility of Neisseria gonorrhoeae isolates and syndromic treatment of men with urethral discharge in Kingston, Jamaica, 2018–19

Cameron-McDermott

Barrow

Webster

et al. 2021

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

Objectives To quantitatively determine the antimicrobial susceptibility of clinical Neisseria gonorrhoeae isolates from men with urethral discharge in Jamaica and to describe the syndromic treatment therapies administered. Methods Urethral eSwabs (Copan) were collected from 175 men presenting with urethral discharge to the Comprehensive Health Centre STI Clinic, Kingston, Jamaica. Clinical information was collected and MICs of eight antimicrobials were determined for N. gonorrhoeae isolates (n = 96) using Etest and interpreted using CLSI criteria. Results The median age of the subjects was 28 years (range: 18–73 years) with a median of 2 sexual partners (range: 1–25) per male in the previous 3 months. All examined N. gonorrhoeae isolates were susceptible to ceftriaxone (96/96), azithromycin (91/91), cefixime (91/91) and spectinomycin (91/91). For ciprofloxacin and gentamicin, respectively, 98.9% (91/92) and 91.3% (84/92) of the isolates were susceptible and 1.1% (1/92) and 8.7% (8/92) showed intermediate susceptibility/resistance. For tetracycline and benzylpenicillin, respectively, 38.0% (35/92) and 22.0% (20/91) of the isolates were susceptible, 52.2% (48/92) and 74.7% (68/91) showed intermediate susceptibility/resistance and 9.8% (9/92) and 3.3% (3/91) were resistant. Syndromic treatment was administered as follows: 93.1% received 250 mg of ceftriaxone intramuscularly plus 100 mg of doxycycline orally q12h for 1–2 weeks and 6.9% received 500 mg of ciprofloxacin orally plus 100 mg of doxycycline orally q12h for 1 week. Conclusions Ceftriaxone (250 mg) remains appropriate for gonorrhoea treatment in the examined population of men in Kingston, Jamaica. Surveillance of N. gonorrhoeae AMR should be expanded in Jamaica and other Caribbean countries to guide evidence-based treatment guidelines.

show abstract

Section: Discussionmentioning

confidence: 89%

Antimicrobial susceptibility of Neisseria gonorrhoeae isolates and syndromic treatment of men with urethral discharge in Kingston, Jamaica, 2018–19

Cameron-McDermott

Barrow

Webster

et al. 2021

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

show abstract

“…Moreover, there are now multiple reports of N . gonorrhoeae strains that are resistant to the last remaining first-line treatment option for gonorrhoea, the extended-spectrum cephalosporins [ 2 – 4 ]. The Centers for Disease Control and Prevention (CDC) have declared drug-resistant N .…”

Section: Introductionmentioning

confidence: 99%

Refinement of immunizing antigens to produce functional blocking antibodies against the AniA nitrite reductase of Neisseria gonorrhoeae

2017

View full text Add to dashboard Cite

The emergence of multi-drug resistant Neisseria gonorrhoeae has generated an urgent need for novel therapies or a vaccine to prevent gonococcal disease. In this study we investigate the potential of targeting the surface exposed nitrite reductase, AniA, to block activity by producing functional blocking antibodies. AniA activity is essential for anaerobic growth and biofilm formation of N. gonorrhoeae and functional blocking antibodies may prevent colonisation and disease. Seven peptides covering regions adjacent to the active site were designed based on the AniA structure. Six of the seven peptide conjugates generated immune responses. Peptide 7, GALGQLKVEGAEN, was able to elicit antibodies capable of blocking AniA activity. Antiserum raised against the peptide 7 conjugate detected AniA in 20 N. gonorrhoeae clinical isolates. Recombinant AniA protein antigens were also assessed in this study and generated high-titre, functional blocking antibody responses. Peptide 7 conjugates or truncated recombinant AniA antigens have potential for inclusion in a vaccine against N. gonorrhoeae.

show abstract

Persistence of an outbreak of gonorrhoea with high-level resistance to azithromycin in England, November 2014‒May 2018

et al. 2018

View full text Add to dashboard Cite

Between November 2014 and May 2018, 118 laboratory-confirmed cases of high-level azithromycin resistant Neisseria gonorrhoeae were identified in England. Cases emerged among heterosexuals in Leeds but spread across England and into sexual networks of men who have sex with men as the outbreak progressed. The few epidemiological links identified indicate substantial under-diagnosis of cases and this, along with the upturn in cases in 2017, highlights the difficulties in controlling the outbreak.

show abstract

Ceftriaxone-resistantNeisseria gonorrhoeae, Puerto Rico

Cited by 3 publications

References 6 publications

Antimicrobial susceptibility of Neisseria gonorrhoeae isolates and syndromic treatment of men with urethral discharge in Kingston, Jamaica, 2018–19

Antimicrobial susceptibility of Neisseria gonorrhoeae isolates and syndromic treatment of men with urethral discharge in Kingston, Jamaica, 2018–19

Refinement of immunizing antigens to produce functional blocking antibodies against the AniA nitrite reductase of Neisseria gonorrhoeae

Persistence of an outbreak of gonorrhoea with high-level resistance to azithromycin in England, November 2014‒May 2018

Contact Info

Product

Resources

About